Matt Zuga - 19 Jan 2022 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
CFO and Chief Business Officer
Signature
/s/ Katie Lapidus, Attorney-in-Fact
Issuer symbol
ABOS
Transactions as of
19 Jan 2022
Transactions value $
$0
Form type
4
Filing time
21 Jan 2022, 15:22:39 UTC
Previous filing
08 Jul 2021
Next filing
03 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABOS Employee Stock Option (right to buy) Award $0 +150K $0.00 150K 19 Jan 2022 Common Stock 150K $5.19 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on January 19, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest and become exercisable each month thereafter, subject to Reporting Person continuing to provide service through each such date.